Brian Markison | Chief Executive Officer |
JD Schaub | Chief Operating Officer |
Mike DePetris | Chief Financial Officer (interim) |
Lisa Wilson | In-Site Communications |
Louise Chen | Cantor Fitzgerald |
Douglas Tsao | HC Wainwright |
Greg Fraser | Truist Securities |
John Vandermosten | Zack’s |
Unknown Analyst | Barclays |
Glen Santangelo | Jefferies |
Good morning everyone. My name is Shelby and I will be your conference Operator.
At this time, I’d like to welcome everyone to the RVL Pharmaceuticals fourth quarter and full year 2022 financial results call.
All lines have been placed on mute to prevent any background noise. After the speakers’ remarks, there will be a question and answer period.